Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy are suboptimal. Targeted treatment with anti-BRAF agents plus anti-EGFR antibodies/chemotherapy have shown promising results based on a smaller number of studies. Here we report a pooled estimate of clinical activity of anti-BRAF agents plus anti-EGFR antibodies/chemotherapy in advanced CRC patients based on published phase II/III trials so far. Methods: PubMed, EMBASE, Cochrane review, and clinicaltrials.gov databases were searched for phase II/III clinical trials studying anti-BRAF agents plus anti-EGFR antibodies/chemotherapy in the second or third line setting for metastatic colorectal cancers. Data were extracted based on Reviews and Meta- Analysis guidelines. DerSimonian-Laird (DL) random effects model was used to estimate the pooled proportion of patients achieving objective response rate (ORR), pooled proportion of patients experiencing therapy related adverse events (TRAEs grade ≥ 3), pooled median progression free survival (PFS) and weights were estimated using inverse variance method. Statistical heterogeneity was calculated using the I2 and chi-squared test. Outcomes were calculated by using ‘Metafor’ and ‘Meta’ packages by R-Studio and “CRAN” project. Results: Four studies with a total of 673 patients who received anti-BRAF agents plus anti-EGFR antibodies/chemotherapy were analyzed. Median age of patients who received treatment was 61 yrs. The pooled proportion of patients who achieved ORR was 21% (95% CI 16% to 25%). Pooled Median PFS was about 4.28 (95% CI, 3.92- 4.6) months and the pooled proportion of patients who experienced adverse events (TRAEs grade ≥ 3) during the treatment was 62% (95% CI 53% to 70%). Conclusions: BRAF-targeted agents plus anti-EGFR antibodies/chemotherapy shown encouraging results with modest improvement in ORR and progression free survival in advanced stage colorectal cancers.